Extended Data Fig. 9Figure 12
Implications of HRD signature on CDK4/6i PFS in g BRCA2 WT breast cancers. HRD inference was performed with an orthogonal method (HRD-IMPACT, see Methods ). This included calculation of large state transitions (LST), telomeric allelic imbalance (TAI) and LOH from samples that passed purity and ASCN imputation QC metrics. The HR was derived using a Cox proportional hazard model ( P from two-sided Wald test). Among g BRCA2 WT patients, HRD was associated with a significantly shorter PFS (HR = 1.78, 95% CI: 1.27 – 2.48, P = 0.00075).